MyFiziq teams up with BioMorphik to share technologies on its medical health and wellness platform
MyFiziq Limited (ASX: MYQ) has signed a binding term sheet with BioMorphikk Pty Ltd, an Australian based behavioural change and technology company that has developed a medical health and wellness platform.
This platform is the bridge between medical and health/wellness. It aims to reduce health costs at all levels of society from the individual, to healthcare and insurance systems, as well as governments.
BioMorphik and MyFiziq will collaborate to integrate MyFiziq’s body tracking application into all of BioMorphik’s verticals, commencing with an initial integration into its pre-emptive health platform over the coming months.
BioMorphik has created a pre-emptive health platform founded on the basis that consistent and early management of health and fitness at younger ages has a compounding effect on health later in life.
Through smaller, constant, micro-interventions BioMorphik can drastically improve lifetime health, reduce the need for medical interventions, and save costs and resources for the user and health systems.
Reduces strain on public and private health infrastructure
The goal of Biomorphik’s pre-emptive health platform is to improve user quality of life, reduce spending on medical treatment, and reduce interactions with the medical system.
With global medical facilities and personnel stretched to their limits and further compounded by a significant worldwide economic downturn and job losses as a result of COVID-19, there should be significant demand for the group’s product offering.
Biomorphik’s solution is a well-designed platform with the intention to improve health outcomes, saving individuals, insurers and governments’ substantial costs, helping to reduce the burden on the global medical facilities and supply chains.
MyFiziq will be an integral part of the BioMorphik direct to consumer offering as the primary checkpoint of identifying and tracking the markers for chronic disease, as well as dimensional and body composition change.
As outlined in the binding terms sheet, the parties will work together to deliver a market-ready integration into the BioMorphik platform by the March quarter of 2021.
In parallel, the parties have agreed to conclude all formal agreements within 60 days of signing the binding terms sheet.
Under the terms of the agreement, BioMorphik has undertaken to deliver a minimum of 100,000 active users within the first 12 months of launch.
Corporate activity highlighted by US$18.5 billion acquisition of Livongo
Commenting on this development and in particular its timing in the current environment MyFiziq chief executive Vlado Bosanac said, “Due to the COVID-19 pandemic, the world has experienced a surge in m-Health, telehealth, virtual care and preventative health investment.
‘’BioMorphik’s behavioural based program targets smaller interventions prior to current preventative healthcare solutions, which is unique and innovative in this urgently needed market segment.
‘’With medical facilities and supply chains strained worldwide as a result of current pandemic, BioMorphik has identified, developed and entered the market with a dynamic and well-resourced offering.
‘’I am pleased to be working with Nathaniel Peek (CEO BioMorphik) and the BioMorphik team to provide an urgently needed, unique behavioural based, pre-emptive health solution that focuses on reducing costs at all levels of the health, wellness and medical supply chain from the user/patient, all the way to the medical provider, insurer and even at government levels.”
Endorsing Bosanac’s comments and underlining the complementary nature of both technologies, Peek said, ‘’Through integrating MyFiziq’s technology into our platform, we now have the capability to more regularly and cost effectively understand user and patient body composition information as well as their risks of chronic disease in real time, capturing their body scans from the privacy of their own home, significantly broadening our B2B (business to business) and B2C (business to consumer) customer reach.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.